FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Federal Register

Guide on Nonclinical Immunotoxic Evaluations

FDA posts a final guidance entitled Nonclinical Evaluation of the Immunotoxic Potential of Pharmaceuticals.

latest-news-card-1
Federal Register

Therapeutic Protein Drug-Drug Interactions Guide

Federal Register notice: FDA makes available a final guidance entitled Drug-Drug Interaction (DDI) Assessment for Therapeutic Proteins.

latest-news-card-1
Federal Register

Guide on Bladder Pain Syndrome Drugs

Federal Register notice: FDA makes available a revised draft guidance entitled Interstitial Cystitis/Bladder Pain Syndrome: Establishing Drug Developm...

latest-news-card-1
Federal Register

Guidance on Drugs for Preventing Migraines

Federal Register notice: FDA makes available a draft guidance entitled Migraine: Developing Drugs for Preventive Treatment.

latest-news-card-1
Human Drugs

FDA Lifts Hold on Multiple Myeloma Drug

FDA removes a two-month-long partial clinical hold on a Molecular Templates Phase 1 multiple myeloma study of MT-0169 that was based on cardiac advers...

latest-news-card-1
Human Drugs

Durbin Urges FDA to Act More on Cancer Drug Shortage

Senator Dick Durbin (D-IL) urges FDA to do more to improve supply shortages of critical cancer drugs.

latest-news-card-1
Biologics

Kyverna Gets Fast Track for Lupus Nephritis Drug

FDA grants Kyverna Therapeutics a fast track designation for KYV-101, an anti-CD19 chimeric antigen receptor T-cell therapy for treating patients with...

latest-news-card-1
Human Drugs

Therapeutic Protein Drug Interaction Assessment Guide

FDA posts a final guidance entitled Drug-Drug Interaction Assessment for Therapeutic Proteins.

latest-news-card-1
Medical Devices

Guidance on Device Pre-Submission Meetings

FDA releases a final guidance entitled Requests for Feedback and Meetings for Medical Device Submissions: The Q-Submission Program.

latest-news-card-1
Human Drugs

Guide on Nonclinical Immunotoxic Evaluations

FDA releases a final guidance entitled Nonclinical Evaluation of the Immunotoxic Potential of Pharmaceuticals.